



## Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Anna G Turkina, Olga Vinogradova, Elza Lomaia, Evgeniya Shatokhina, Oleg Shukhov, Ekaterina Chelysheva, Irina Nemchenko, Anna Petrova, Anastasiya Bykova, Andrey Zaritskey, Nadia Siordia, Dzhariyat Shikhbabaeva, Vasily Shuvaev, Jorge E. Cortes, Robert Peter Gale, Michele Baccarani, Oliver G. Ottmann, Ilya Mikhailov, Fedor Novikov, Veronika Shulgina, and Ghermes Chilov

Blood 2018 132:790; doi: <https://doi.org/10.1182/blood-2018-99-116803>

Article

Info & Metrics

### Abstract

**Background:** PF-114 mesylate is a 4<sup>th</sup>-generation oral tyrosine kinase-inhibitor (TKI) active against wild-type and mutated *BCRABL1* isoforms including those with a *BCRABL1*<sup>T315I</sup>. We present data from a phase-1 study in subjects with chronic or accelerated phase chronic myeloid leukaemia (CML) failing  $\geq 2$  TKIs or who have *BCRABL1*<sup>T315I</sup> (NCT02885766).

**Methods:** 3+3 dose-escalation design to determine maximum tolerated dose (MTD) followed by expanded cohorts for doses  $\leq$  MTD. The primary objective was to determine the MTD and identify dose-limiting toxicities (DLTs) during cycle 1 (28 days). Secondary objectives included safety and anti-CML activity based on hematological, cytogenetic, and molecular criteria. Adverse events (AEs) were assessed and graded using NCI-CTCAE v4.03.

**Results:** 51 subjects were enrolled as of June 26, 2018. Daily doses were 50 mg (n=3), 100 mg (n=3), 200 mg (n=9), 300 mg (n=11), 400 mg (n=12), 500 mg (n=3), 600 mg (n=6), 750 mg (n=4) given on a continuous QD schedule. Median age was 50 years (range, 29–82 years). Median interval from diagnosis to study-entry was 10 years (range, 0–23 years). Subjects had baseline ECOG performance scores  $< 2$ . 13 subjects were reported to have *BCRABL1*<sup>T315I</sup>. Subjects were heavily pre-treated: 25 had received  $\geq 3$  prior TKIs; 5 subjects with *BCRABL1*<sup>T315I</sup> received 1 prior TKI. 600 mg was identified as the MTD with 1 of 6 subjects experiencing a DLT at this dose (Gr 3 psoriasis-like skin lesion). Similar grade-3 skin lesions were also identified at the dose of 750 mg in 2 subjects and at 400 mg in 1 subject. Therapy is ongoing in 23 subjects at doses 200, 300 and 400 mg with median duration of exposure of 5 (range, 1–21), 3 (range, 1–12) and 4 (range, 1–19) cycles. Other subjects discontinued because of progression (n=16), AEs (n=6) or other reasons (n=6). The most common of non-hematologic toxicity was skin toxicity, which was common at doses of  $\geq 400$  mg. Grade-3 skin toxicity occurred in 3 subjects on daily dose 750 mg, 4 subjects on dose 600 mg, 1 patient on dose 500 mg and 3 subjects on dose 400 mg. Skin lesions resolved rapidly upon drug discontinuation and topical therapy. No other drug related non-hematologic grade-3 toxicities except a single case of grade-3 hepatitis on dose 400 mg were observed. No deterioration of ankle-brachial index or vascular occlusive events were observed. A complete hematologic response was achieved in 8 of 19 evaluable subjects including 3 of 8 with *BCRABL1*<sup>T315I</sup>. Major cytogenetic response was achieved in 6 of 21 evaluable subjects including 3 of 7 with *BCRABL1*<sup>T315I</sup>. Major molecular response was achieved in 2 of 18 subjects completing  $\geq 13$  cycles. Most cytogenetic and molecular responses were achieved at doses 200 and 300 mg which were well-tolerated and will be considered for the phase-2 study.

**Conclusion:** MTD of PF-114 is 600 mg with skin toxicity as the DLT. The best safety/efficacy ratio was seen at doses of 200–300 mg which are being studied in expanded cohorts and soon in a phase-2 study.

**Disclosures Turkina:** *Novartis*: Other: provided consultations; *Bristol Myers Squibb*: Other: provided consultations; *Phizer*: Other: provided consultations; *Fusion Pharma*: Other: provided consultations. **Shukhov:** *Novartis*: Other: provided consultations and performed lectures ; *Bristol Myers Squibb*: Other: provided consultations and performed lectures . **Chelysheva:** *Bristol Myers Squibb*: Other: provided consultations and performed lectures; *Fusion Pharma*: Other: provided consultations ; *Novartis*: Other: provided consultations and performed lectures. **Cortes:** *Daiichi Sankyo*: Consultancy, Research Funding; *Astellas Pharma*: Consultancy, Research Funding; *Novartis*: Consultancy, Research Funding; *Pfizer*: Consultancy, Research Funding; *Arog*: Research Funding. **Ottmann:** *Novartis*: Consultancy; *Pfizer*: Consultancy; *Takeda*: Consultancy; *Amgen*: Consultancy; *Celgene*: Consultancy, Research Funding; *Incyte*: Consultancy, Research Funding; *Fusion Pharma*: Consultancy, Research Funding. **Mikhailov:** *Fusion Pharma*: Employment. **Novikov:** *Fusion Pharma*: Employment. **Shulgina:** *Fusion Pharma*: Employment. **Chilov:** *Fusion Pharma*: Employment.



Take **notes**, share and follow articles, make **comments**, and collaborate with peers!



- ↱\* Asterisk with author names denotes non-ASH members.

© 2018 by The American Society of Hematology

### Potential Articles of Interest

PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy

*Editors' Choice.* Andrey Zaritsky et al., *Blood*

ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single-Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy

Hironobu Minami et al., *Blood*

Second Generation Tyrosine Kinase Inhibitors (2G-TKI) in the Frontline Treatment of Elderly Patients with Chronic Myeloid Leukemia

Fabio Stagno et al., *Blood*

Kinetics of the Leukemic Clone in Patients with Chronic Myeloid Leukemia during Pregnancy

Ekaterina Chelysheva et al., *Blood*

A Phase I Study of the HDAC Inhibitor LBH589 in Combination with Imatinib for Patients with CML in Cytogenetic Remission with Residual Disease Detectable by Q-PCR.

Ravi Bhatia et al., *Blood*

Safety assessment of the aqueous extract of the flowers of *Nymphaea lotus* Linn (Nymphaeaceae): Acute, neuro- and subchronic oral toxicity studies in albinos Wistar rats

Mireille Kameni Poumeni et al., *Journal of Complementary and Integrative Medicine*

Protection against arsenic-induced hematological and hepatic anomalies by supplementation of vitamin C and vitamin E in adult male rats

Rubia Mondal et al., *Journal of Basic and Clinical Physiology and Pharmacology*

Toxicological evaluation of the aqueous extract of *Acalypha wilkesiana* in Wistar albino rats

Johnny Olufemi Olukunle et al., *Journal of Complementary and Integrative Medicine*

Early responses to adenoviral-mediated transfer of the aquaporin-1 cDNA for radiation-induced salivary hypofunction.

Bruce J Baum et al., *Proc Natl Acad Sci U S A*

Safety and pharmacokinetics of a kinin B1 receptor peptide agonist produced with different counter-ions


Martin Savard et al., *Biological Chemistry*

Powered by **TREND MD**

▲ [Back to top](#)

Advertisement

◀ [Previous](#)



[Table of Contents](#)

**Volume:** 132


**Issue:** Suppl 1

**Pages:** 790

**DOI:** <https://doi.org/10.1182/blood-2018-99-116803>

 [Email](#)

 [Alerts](#)

 [Citation Tools](#)

 [Cite This](#)

 [Request Permissions](#)

 [Share](#)

[Tweet](#)

[Hpaab](#)

[G+](#)

**Jump to**

 [Article](#)

 [Info & Metrics](#)

 **Related Articles**

*No related articles found.*

Advertisement

[Current Issue](#)

[First Edition](#)

[Collections](#)

[All Issues](#)

[Abstracts](#)

[Video Library](#)

[About \*Blood\*](#)

[Subscriptions](#)

[Newsroom](#)

[Copyright](#)

[Public Access](#)

[Permissions](#)

[Submit to \*Blood\*](#)

[Blood App](#)

[Alerts](#)

[RSS](#)

[Contact Us](#)

[Order Reprints](#)

**Information for:**

[Authors](#)

[Subscribers](#)

[Institutions/Librarians](#)

[Advertising in \*Blood\*](#)

[Terms and Conditions](#)

Blood Journals      

---

Advertisement

Copyright © 2018 by American Society of Hematology

[Privacy Policy](#) | [Terms of Service](#) | [Contact Us](#)

---

